Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dorgenmeltucel-L - Lumos Pharma

Next Previous
X
Search
Drug Profile

Dorgenmeltucel-L - Lumos Pharma

Alternative Names: HyperAcute Melanoma; Melanoma immunotherapy - Lumos Pharma; NLG-12036

Latest Information Update: 27 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NewLink Genetics Corporation
  • Developer Lumos Pharma; NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 07 Aug 2015 Dorgenmeltucel-L is still in phase II trials for Malignant melanoma in the USA
  • 25 Feb 2014 NewLink Genetics Corporation plans a phase IIb trial for Malignant melanoma in USA (NCT02054520)
  • 01 Jun 2012 Final efficacy, immunogenicity and adverse events data from a phase II trial in Malignant melanoma presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top